[Treatment for acute respiratory viral infection and influenza in daily clinical practice: Results of the multicenter international observational FLU-EE study]. / Lechenie bol'nykh ORVI i grippom v povsednevnoi klinicheskoi praktike (rezul'taty mnogotsentrovogo mezhdunarodnogo nablyudatel'nogo issledovaniya FLU-EE).

PURPOSE: To study the clinical aspects of influenza and acute respiratory viral infection (ARVI) in routine clinical practice, with efficacy and safety of the antiviral therapy evaluation. SUBJECTS AND METHODS: In the large multicenter prospective observational study were enrolled 18,946 patients aged 18 to 93 years with previously determined diagnosis of influenza or ARVI from 262 outpatient sites in Russia, Armenia, Moldova and Georgia. According to study design, 3 visits were evaluated. On each visit the detailed medical examination, determination of individual symptoms' severity and course of disease were made. The dynamic evaluation of prescribed in routine clinical practice therapy of influenza and ARVI and cases of disease exacerbations with antibiotics concomitant therapy were assessed. RESULTS: For the first time in outpatient practice on a large population of adult patients the objective data were obtained and analyzed. This data relating to the timing of access to medical care of patients with influenza and ARVI depending on the age and the disease severity, dynamics of clinical picture of the disease, their outcomes, timing recovery, as well as ongoing drug therapy of ARVI and influenza, allowed to identify patterns of development and course of these diseases. The effectiveness and safety of antiviral drug Kagocel for treatment of ARVI and influenza was shown. This is reflected in the improvement of the clinical picture of the disease; reducing the number of patients with exacerbations, requiring the prescription of systemic antibiotics up to 1.5 times; the acceleration of regression of symptoms and recovery periods. CONCLUSION: This study allows increase the level of objective assessment of the beginning and course of influenza and other ARVIs in outpatient practice, to predict their course and outcome, and to improve the treatment.

[Applying of recombinant interleukin-1ß to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].

UNLABELLED: The search for rational treatment of CHC patients, non-response to the primary antiviral therapy especially with unfavorable genotypes for interleukin-28B, remains valid. PURPOSE: To evaluate the efficacy and safety of recombinant IL-1ß (Betaleukin) in combined antiviral therapy in patients with chronic hepatitis C who did not respond to previous treatment. The study included 26 patients with HCV-1. Patients were divided into 2 groups depending on retreatment scheme: group 1 (n = 10) was treated with recombinant IFN-a2b ("Interal"-P) 5 million IU daily subcutaneously for 12 weeks then every other day until the end of treatment; ribavirin, depending on body weight (800-1200 mg/day) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day for 12 weeks (45 injections); group 2 (n = 16)--recombinant IFN-a2b ("Interal"-P) 3 million IU every other day subcutaneously for 48 weeks; ribavirin--1000 mg/day (for a body weight < 75 kg), 1200 mg/day (for a body weight > 75 kg) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day, five courses for 3 weeks (50 injections). RESULTS: Combined antiviral therapy (α-IFN2b and RIB) with IL-1ß (Betaleukin) in patients who had not responded to previous therapy, with a predominance of unfavorable genetic background for IL-28B typing helped to improve SVR (44%) with more efficient 45-day administration of the medications in the first 12 weeks in combination with inductive α-IFN therapy and achieve biochemical response at week 24 of treatment. Adverse effects of the IL-1ß mainly limited with fever, moderate local reactions and do not require discontinuation of treatment.

[The chronic form of tick-born encephalitis with a clinical manifestation of disseminated encephalomyelitis (case description)].

In most cases, the chronic form of tick-born encephalitis (CTBE) develops after the acute phase of the disease and is characterized by polymorphic clinical manifestations. It is not often to see patients with disseminated encephalomyelitis in case of CTBE. We describe a patient with CTBE developed 12 years after the acute phase of the disease, which had a remitting course and clinically revealed multifocal lesions. MRI lesions did not differ from those caused by multiple sclerosis and the differential diagnosis of the latter was performed. The analysis of epidemiological data as well as the standard neurological examination in combination with the laboratory diagnostic methods allowed us to confirm the diagnosis of CTBE.

[Pegylated intereferon hematological safety in comparison with standard].

Comparative analysis of adverse hematologic effects in 135 patients with with chronic hepatits C on combined antiviral therapy of pegylated and "short lived" forms of alpha-interferon in combination with ribavirin was investigated. As a result of the comparison, the response to antiviral therapy in patients with chronic hepatitis C treated with daily administration of simple interferon-alpha in hematologic data is similar in patients undergoing treatment with pegylated drugs.